Development of PKN2 selective inhibitors, which do not exhibit the confounding off-target effects of currently available compounds, such as Y27632, Fasudil, and PKC412, would provide a pharmacological route for addressing specific PKN2 roles in tumor biology (Falk et al., 2014). This evidence concerns the gene PKN2 and neoplasm.